Healthcare

Healthcare

Merck Preps for End of Keytruda Exclusivity with $6.7B Deal for Leukemia Treatment

Photo via Anthony Behar/Sipa USA/Newscom

The key patent protections on Keytruda, Merck’s immunotherapy treatment that outsold all other prescription drugs last year, ends in 2028.

1 min read

Photo via Gado Images/Smith Collection/Gado/Sipa USA/Newscom

Healthcare

GLP-1 Race Heats Up with Positive Test Results for Next-Gen Eli Lilly Drug

Approximately one in eight Americans are taking medications like Ozempic or Wegovy for weight loss, diabetes, heart disease and more.

2 min read
Photo via Michael Siluk/UCG/Universal Images Group/Newscom

Healthcare

Hims Teams up with Novo to Compete for Weight Loss Scripts

The two struck a deal Monday for Hims to offer official versions of Novo Nordisk’s GLP-1 drugs Ozempic and Wegovy.

2 min read
Photo via Gado Images/Smith Collection/Gado/Sipa USA/Newscom

Healthcare

Eli Lilly Widens Access to Weight-Loss Injectable as Lower-Cost Pill Nears Approval

Just 20% of firms with 200 or more workers said they covered GLP-1 drugs for weight loss, according to the Peterson-KFF Health System Tracker.

2 min read

Healthcare

Neurotech Startup Treating Blindness Nabs $1.5 Billion Valuation

Photo via Science Corporation

Science Corp., a brain-implant startup developing a device that can enable blind people to see again, just raised $230 million from investors.

2 min read

Healthcare

Novo Nordisk Launches Suit to Knock Out Hims & Hers’ Weight Loss Knockoffs

Photo via Ritzau Scanpix/Sipa USA/Newscom

Novo’s Copenhagen-listed shares rose 5.2% on Monday. New York-listed shares in Hims & Hers, meanwhile, shed an Ozempic-like 16% in volume.

2 min read

Technology

Wearable Wellness Devices Dominate CES as FDA Loosens Rules

Photo via Xinhua/Sipa USA/Newscom

Just last year, the FDA sent a warning letter to wellness wearable firm Whoop after it rolled out a feature to check users’ blood pressure.

1 min read

Sign Up for The Daily Upside to Unlock This Article

Sharp news & analysis on finance, economics, and investing.